Hill Democrats Continue Inquiries Into High Prices For New Versions Of Old Drugs; Avanir's Nuedexta And URL Pharma's Colcrys Targeted
This article was originally published in The Pink Sheet Daily
Executive Summary
Letters from Sen. Kohl and Reps. Waxman, Pallone and DeGette are reminiscent of the recent uproar over pricing for KV's Makena.
You may also be interested in...
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
Colcrys Promo Eats Pavement As FDA Objects To Ad Of Motorcyclist Holding Teacup
FDA asks Mutual to stop using a pharmacy sell sheet that describes the gout drug as “gentle.” It also cites a video for failing to convey serious risk information and suggesting the drug is as tolerable as a placebo and superior to NSAIDs.